Brief: Dawnrays Pharmaceutical Posts HY Profit Attributable Of RMB171.7 Million
26/08/2022 14:10
Aug 26 (Reuters) - Dawnrays Pharmaceutical (Holdings) Ltd
2348.HK :
* HY PROFIT ATTRIBUTABLE RMB171.7 MILLION VERSUS RMB166.6
MILLION
* HY REVENUE RMB623.5 MILLION VERSUS RMB608.6 MILLION
* DECLARED AN INTERIM DIVIDEND OF HK$0.015 PER SHARE
Source text for Eikon: urn:newsml:reuters.com:*:nHKSS9FdJ
Further company coverage: 2348.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Dawnrays Pharmaceutical (Holdings)
See all newsBrief: Dawnrays Pharmaceutical Says Suzhou Dawnrays Commits To Invest Up To RMB100 Mln In Partnership
Brief: Dawnrays Pharmaceutical (Holdings) Final Dividend Of Hk$0.048 Per Share
Brief: Dawnrays Pharmaceutical Reports HY Net Income Attributable Of RMB104.6 MLN
Brief: Dawnrays Pharmaceutical (Holdings) Posts FY Profit Attributable Of Rmb564.9 Million
Brief: Dawnrays Pharmaceutical (Holdings) Appoints Yu Liwei To Act As CEO